A Whale Spends $2 Million to Acquire 5.57 Million AI16Z

Biopharmaceutical company Soligenix, Inc. recently announced that its application for orphan drug designation for SGX945, developed for the treatment of Behçet's Disease, has received a positive opinion from the European Medicines Agency (EMA).

Cheniere Energy Inc announced that it has increased the total authorized amount for its stock repurchase program to over $10 billions, effective through 2030.

Installed Building Products, Inc. has set a clear growth blueprint for 2026, with the company expecting to achieve at least $100 million in annual revenue growth through acquisitions.

Crescent Biopharma Inc recently disclosed that certain revenues recognized in its 2025 financial report actually originate from a $20 million upfront payment made by Kelun-Biotech under a licensing agreement between the two parties for the core asset Cr-001.